ALLIANCEBERNSTEIN L.P. - LINEAGE CELL THERAPEUTICS IN ownership

LINEAGE CELL THERAPEUTICS IN's ticker is LCTX and the CUSIP is 53566P109. A total of 105 filers reported holding LINEAGE CELL THERAPEUTICS IN in Q3 2023. The put-call ratio across all filers is - and the average weighting 0.1%.

Quarter-by-quarter ownership
ALLIANCEBERNSTEIN L.P. ownership history of LINEAGE CELL THERAPEUTICS IN
ValueSharesWeighting
Q3 2023$20,921
+14.7%
17,730
+37.0%
0.00%
Q2 2023$18,245
-56.6%
12,940
-52.9%
0.00%
Q1 2022$42,000
-49.4%
27,500
-18.6%
0.00%
Q4 2021$83,000
-2.4%
33,8000.0%0.00%
Q3 2021$85,000
-11.5%
33,8000.0%0.00%
Q2 2021$96,000
+15.7%
33,800
-66.3%
0.00%
Q1 2020$83,0000.0%100,200
+8.0%
0.00%
Q4 2019$83,000
-8.8%
92,8000.0%0.00%
Q3 2019$91,00092,8000.00%
Other shareholders
LINEAGE CELL THERAPEUTICS IN shareholders Q3 2023
NameSharesValueWeighting ↓
BROADWOOD CAPITAL INC 34,935,485$39,477,0003.01%
Raffles Associates 2,080,536$2,351,0002.51%
Defender Capital, LLC. 5,184,035$5,862,0002.30%
Prescott General Partners LLC 1,851,851$2,093,0000.16%
DAFNA Capital Management LLC 140,000$158,0000.04%
Fort Sheridan Advisors LLC 83,931$95,0000.03%
Long Focus Capital Management, LLC 215,000$243,0000.02%
XTX Topco Ltd 72,807$82,0000.02%
Ergoteles LLC 490,895$555,0000.02%
Beirne Wealth Consulting Services, LLC 45,000$51,0000.02%
View complete list of LINEAGE CELL THERAPEUTICS IN shareholders